Progyny (NASDAQ:PGNY) Posts Better-Than-Expected Sales In Q4, Stock Jumps 14.7%
Fertility benefits company Progyny (NASDAQ:PGNY) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.6% year on year to $298.4 million. On top of that, next quarter’s revenue guidance ($309 million at the midpoint) was surprisingly good and 10.3% above what analysts were expecting. Its non-GAAP profit of $0.42 per share was 13.5% above analysts’ consensus estimates.